Finanzen von Pulmonx Corp (LUNG)LUNGPulmonx Corp

Evaluating the bottom line, Pulmonx Corporation maintains a gross margin of 76.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32.80%, while the net margin is -36.76%. These profitability ratios, combined with a Return on Equity (ROE) of -90.31%, provide a clear picture of how effectively LUNG converts its operational activities into shareholder value.

In the context of the broader market, LUNG competes directly with industry leaders such as HSDT and CATX. With a market capitalization of $109.95M, it holds a significant position in the sector. When comparing efficiency, LUNG's gross margin of 76.19% stands against HSDT's 96.95% and CATX's 100.00%. Such benchmarking helps identify whether Pulmonx Corporation is trading at a premium or discount relative to its financial performance.

Pulmonx has shown a gross margin improvement, reaching 77.97% in Q2 2026, despite a revenue decline of 5% year-over-year. The net loss has narrowed to $8.39 million in Q3 2026 from larger losses in previous quarters, indicating potential recovery.